Современные направления лечения нейроэндокринных опухолей

1. Binderup T, Knigge U, Loft A, Federspiel В. 18F-Fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors. Clin Cancer Res 13 (30): 978–85.
2. Strosberg JR, Choi J, Cantor AB et al. Selective hepatic artery embolization for treatment of patients with metastatic carcinoid and pancreatic endocrine tumors. Cancer Control 2006; 13: 72–8.
3. Moertel CG, Johnson CM, McKusick MA et al. The management of patients with advanced carcinoid tumors and islet cell carcinomas. Ann Intern Med 1994; 120: 302–9.
4. Sarmiento JM, Heywood G, Rubin J et al. Surgical treatment of neuroendocrine metastases to the liver: A plea for resection to increase survival. J Am Coll Surg 2003; 197: 29–37. [CrossRef][Medline].
5. Osborne DA, Zervos ЕЕ, Strosberg J et al. Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors. Ann Surg Oncol 2006; 13: 572–81. [CrossRef][Medline].
6. Rubin J, Ajani J, Schirmer W et al. Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. J Clin Oncol 1999; 17: 600–6.
7. Oberg K, Kvols L, Caplin M et al. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol 2004; 15: 966–73.
8. Schmid HA. Pasireotide (SOM230): Development, mechanism of action and potential applications. Mol Cell Endocrinol 2008; 286: 69–74.
9. Gustaffson B, Hauso O, Kidd M, Modlin M. Carcinoid hart disease. In A century advances in neuroendocrine tumor. Biology and treatment Modlin J, Oberg K 2007; 288–97.
10. Krenning EP, Bakker WH, breeman WA et al. Localisation of endocrine-related tumors with radioiodinated analogue of somatostatin. Lancet 1989; 1: 242–4.
11. Van Essen M, Krenning EP, De Jong M et al. Peptide receptor radionuclide therapy with radiolabeled somatostatin analogues in patients with somatostatin receptor positive tumours. Acta Oncol 2007; 46:723–734. [CrossRef][Medline].
12. Kwekkeboom DJ, Teunissen JJ, Bakker WH et al. Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol 2005; 23: 2754–62.
13. Kwekkeboom DJ, de Herder WW, Kam BL et al. Treatment with the radiolabeled somatostatin analog [177Lu-DOTA 0,Tyr3]octreotate: Toxicity, efficacy, and survival. J Clin Oncol 2008; 26: 2124–30.
14. van Essen M, Krenning EP, Kam BL et al. Report on short-term side effects of treatments with 177Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2008; 35: 743–8.
15. Anthony LB, Woltering EA, Espenan GD et al. lndium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies. Semin Nucl Med 2002; 32: 123–32.
16. Otte A, Herrmann R, Heppeler A et al. Yttrium-90 DOTATOC: first clinical results. Eur J Nucl Med 1999; 26: 1439–47.
17. Waldherr C, Pless M, Maecke HR et al. The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study. Ann Oncol 2001; 12: 941–5.
18. Oberg K, Funa K, Aim G. Effects of leukocyte interferon on clinical symptoms and hormone levels in patients with mid-gut carcinoid tumors and carcinoid syndrome. N Engl J Med 1983; 309: 129–33.
19. Oberg K. Interferon in the management of neuroendocrine GEP-tumors: A review. Digestion 2000; 62 (suppl l): 92–7.
20. Kolby L, Persson G, Franzen S et al. Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours. Br J Surg 2003; 90: 687–93.
21. Faiss S, Pape UF, Bohmig M et al. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors: The International Lanreotide and Interferon Alfa Study Group. J Clin Oncol 2003; 21: 2689–96.
22. Moertel CG, Kvols LK, O'Connell MJ et al. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin: Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 1991; 68: 227–32.
23. Sun W, Lipsitz S, Catalano P et al. Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group study E1281. J Clin Oncol 23: 2005; 4897–904.
24. Bukowski RM, Tangen CM, Peterson RF et al. Phase II trial of dimethyltriazenoimidazole carboxamide in patients with metastatic carcinoid: A Southwest Oncology Group study. Cancer 1994; 73: 1505–8.
25. Kulke MH, Stuart K, Enzinger PC et al. Phase II study of temozolomide and thalidimide in patients with metastatic neuroendocrine tumors. J Clin Oncol 2006; 24: 401–6.
26. Ansell SM, Pitot HC, Burch PA et al. A phase II study of high-dose paclitaxel in patients with advanced neuroendocrine tumors. Cancer 2001; 91: 1543–8.
27. Kulke MH, Kim H, Stuart K et al. A phase II study of docetaxel in patients with metastatic carcinoid tumors. Cancer Invest 2004; 22: 353–9.
28. Kulke MH, Kim H, Clark JW et al. A phase II trial of gemcitabine for metastatic neuroendocrine tumors. Cancer 2004; 101: 934–9.
29. Касчито Д., Ловитс Б. Редкие опухоли. В кн.: Онкология. Под ред. Касчито Д. М., 2008; 541–50.
30. Wetzels С, Jolanda GM. Hoefnagel et al. Ultrastructural Proof of Polyomavirus in Merkel Cell Carcinoma Tumour Cells and Its Absence in Small Cell Carcinoma of the Lung. Melchers Research Article, published 23 Mar 2009.
31. Pinchot SN, Kunnimalaiyaan M, Sippel R. Medullary thyroid carcinoma: targeted and future directions. J Oncol 2009; p. 7.
32. Румянцев П.О., Ильин А.А., Румянцева У.В., Саенко В.А. Рак щитовидной железы. Современные подходы к диагностике и лечению. М., 2009; 110–21; 325–36.
33. Yao JC, Phan A, Hoff PM et al. Targeting vascular endothelial growth factor in advanced carcinoid tumor: A random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol 2008; 26: 1316–23.
34. Kulke MH, Lenz HJ, Meropol NJ et al. Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol 2008; 26: 3403–10.
35. Park K-S, Lee J-L, Ahn H et al. Sunitinib, a novel therapy for anthracycline- and cisplatin-refractory malignant pheochromocytoma. Jap J Clin Oncol 2009; 39 (5): 327–31.
36. Joshua AM, Ezzat S, Asa SL et al. Rationale and evidence for sunitinib in the treatment of malignant paraganglioma/pheochromocytoma. J Clin Endocrinol Metabol 1 (94): 5–9.
37. Yao J, Lombard-Bohas C, Baudin E et al. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II Trial. J Clin Oncol 2010; 1 (28): 69–76.

В.А.Горбунова, Н.Ф.Орел, А.Е.Кузьминов

РОНЦ им. Н.Н.Блохина РАМН, Москва